Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.

ABSTRACT:

Abstract

Although ERBB2 (HER2) is an established oncogenic driver and therapeutic biomarker in several cancers, current drug approvals do not reflect the diverse spectrum of activating alterations across indications in which HER2-targeted therapies may yield clinical benefit. In most cancer types, HER2 status is defined by HER2 overexpression/amplification assessed by IHC and FISH, which do not provide genomic context. We sought to define the pan-tumor landscape of activating ERBB2 and ERBB3 genomic alterations detected by comprehensive genomic profiling (CGP). We queried institutional databases of solid tumor CGP, including 429,666 patients who underwent Foundation Medicine testing and 83,332 patients whose tumors were profiled using Memorial Sloan Kettering Integrated Mutation Pr

SUBMITTER: Liu D 

PROVIDER: S-EPMC12022956 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature